Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Practical aspects of the “new” IND Rule

Posted on May 23rd, 2016 by

Pharmacovigilance

Medical-safety-2

The FDA IND reporting rule[i], mandatory since March 2011, has had a major impact on the sponsor’s responsibilities to report safety information representing a potential change in the risk profile for products that are under investigation. (more…)

Biosimilars and Pharmacovigilance: What’s Ahead

Posted on May 20th, 2016 by

Pharmacovigilance

DNA Magnification

DNA Magnification

In our first blog in this series, we drew from a recent IMS report  to demonstrate the market potential of biosimilars. (more…)

Molecular Relatives: Prodrugs

Posted on May 19th, 2016 by

Pharma R&D

molecule

I’m an avid sailor, and on our boat we have an amazing device known as a water-maker. It is probably one of the most useful pieces of equipment on board for long cruises, as it takes in sea water, and, through a process of reverse osmosis, provides potable drinking water. (more…)

Can a mosquito change the world?

Posted on May 18th, 2016 by

Chemistry

feeding_mosquito

It is night, you are trying to sleep and you hear a mosquito in your bedroom. Can you sleep? (more…)

The Role of Scientific Literature in Pharmacovigilance: Challenges and Solutions

Posted on May 6th, 2016 by

Pharmacovigilance

Medical-Literature

After our recent webinar, Elsevier received several questions from attendees. During the next few weeks, we will discuss some of the questions in more detail.  (more…)

Using Text Mining to Find Treatments for Rare Diseases

Posted on May 5th, 2016 by

Pharma R&D

Findacure UK Cure CHI

When you compare PubMed search results for rare diseases, such as “congenital hyperinsulinism” (767), schwannomatosis (250) or “Mabry syndrome” (34), to that of “diabetes” (542,987), “heart attack” (217,694) or “obesity” (237,307), the disparity in attention becomes much more obvious. (more…)

  1. 1
  2. …
  3. 65
  4. 66
  5. 67
  6. 68
  7. 69
  8. …
  9. 77


About this Blog

iStock_000019748868_Full

The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.